Abstract
Feline immunodeficiency virus (FIV), the lentivirus of domestic cats responsible for feline AIDS, establishes a latent infection in peripheral blood CD4+ T-cells approximately eight months after experimental inoculation. In this study, cats experimentally infected with the FIV-C strain in the asymptomatic phase demonstrated an estimated viral load of 1 infected cell per approximately 103 CD4+ T-cells, with about 1 copy of viral DNA per cell. Approximately 1 in 10 proviral copies was capable of transcription in the asymptomatic phase. The latent FIV proviral promoter was associated with deacetylated, methylated histones, which is consistent with a condensed chromatin structure. In contrast, the transcriptionally active FIV promoter was associated with histone acetylation and demethylation. In addition, RNA polymerase II appeared to be paused on the latent viral promoter, and short promoter-proximal transcripts were detected. Our findings for the FIV promoter in infected cats are similar to results obtained in studies of human immunodeficiency virus (HIV)-1 latent proviruses in cell culture in vitro studies. Thus, the FIV/cat model may offer insights into in vivo mechanisms of HIV latency and provides a unique opportunity to test novel therapeutic interventions aimed at eradicating latent virus.
Keywords: FIV, latency, lentivirus, chromatin, transcription, CD4 T-cells
1. Introduction
Feline immunodeficiency virus (FIV) is a lentivirus of domestic cats similar to human immunodeficiency virus (HIV) in genome structure and immunopathogenesis [1,2], and has been utilized as the only naturally occurring animal model of immunodeficiency for HIV infection in people [3]. Studies in our laboratory demonstrated that domestic cats experimentally infected with FIV enter a state of latency in peripheral blood CD4+ T-cells with concurrent undetectable plasma viremia approximately eight months after inoculation. Thus, FIV infection of its natural host can provide critical insight into generalizable mechanisms of lentiviral latency and allow for the investigation of novel therapeutics targeting latent viral reservoirs.
2. Viral Load
To further characterize the latent FIV reservoir during chronic infection, viral DNA loads were quantified in peripheral CD4+ T-cells using limiting dilution real-time PCR. CD4+ T-lymphocytes were isolated from the peripheral blood of four cats experimentally infected with FIV-Cpgmr [4] in the asymptomatic phase (28–32 months post inoculation) using dual magnetic column separation [5]; flow cytometry showed that the enriched cell population was greater than 97% CD4+ T-cells. Analyses were performed on total CD4+ T cells; within the limitations of the assay, further definition of CD4+ T cell sub-populations was not possible. Approximately 106 CD4+ T-cells from each cat were serially diluted ten-fold down to 100 cells for subsequent DNA isolation (DNA Micro Kit, Qiagen). DNA copy number was measured by real-time PCR for the capsid open reading frame of FIV gag and for a portion of the feline interleukin (IL)-2 gene (Figure 1), as previously described [5]. An average of 0.0013 (standard deviation ±0.0005) FIV copies per cellular equivalents (copies of IL-2 divided by 2) were detected and equated to one FIV proviral gag copy per 770 (~103) CD4+ cellular equivalents. Thus, the amount of FIV proviral genome copies was ~3 logs less than cellular equivalents with FIV gag signal detectable at 104 cells but lost at 103 cells. Based on the limit of detection of ~101 copies FIV gag DNA for this assay, we can conclude that on average there was only one provirus per infected cell, and one infected cell per 103 CD4+ T-cells. In other words, in 103 cells we would expect on average one copy of FIV gag as long as there is only one copy of FIV per infected cell; but given that one copy of gag is below our limit of detection, 104 cells would be the necessary to detect FIV DNA (which we found to be the case). The FIV proviral DNA load in peripheral CD4+ T-cells was similar to that of HIV-infected humans in the asymptomatic phase [6,7]. It has been suggested that the FIV-Cpgmr isolate is highly virulent [8]; thus, it is unknown whether the proviral loads found here would be similar for other strains of FIV. Though we have previously demonstrated a lack of 2-LTR circle junctions in cells latently infected with FIV [5], it should be noted that the PCR assay used here does not discriminate between integrated and unintegrated viral species such that these figures may provide an over-estimation of proviral load.
To determine the amount of replication competent virus in this reservoir, CD4+ T-cells were isolated from two of the four FIV-infected cats (34–37 months post inoculation) as above, serially diluted from 106 down to 102 cells and cocultured with specific pathogen-free (SPF) feline peripheral blood mononuclear cells (PBMC) for 21 days in mitogen (phorbol myristate acetate and concanavalin A)-containing medium. Supernatant samples were removed on culture days 7, 14, and 21 for DNA and RNA isolation (AllPrep DNA/RNA mini kit, Qiagen), which were assayed for FIV gag RNA and 2-LTR circle junctions via real-time PCR [5]. On culture days 7 and 21, clarified supernatants were transferred to cultures of fresh SPF feline PBMC and assayed for FIV gag DNA after 7 days of incubation. CD4+ T-cells from both cats were initially negative for both FIV RNA and 2-LTR circle junctions (day 0). After 21 days in culture, cultures of as little as 104 CD4+ T-cells from FIV-infected cats were positive for FIV RNA, while cultures containing 105 cells demonstrated infectious supernatants and 2-LTR circle junctions (Table 1). Given that there is approximately one provirus in every 103 CD4+ T-cells (above), these data indicate that approximately 1 in every 10 proviruses is capable of transcription, but, similar to HIV [6,9], only about 1 in 100 proviruses is fully replication competent. Limited sensitivity of the supernatant transfer assay, or viral replication restricted to cell-to-cell spread, may account for the differences among levels of viral RNA, 2-LTR circle junctions, and infectious supernatant observed at the 104 and 105 CD4+ T-cell dilutions.
Table 1.
Cat Number | Starting CD4+ T-cells | FIV gag RNA | 2-LTR Circle Junction | Infectious Supernatant | |||||
---|---|---|---|---|---|---|---|---|---|
d7 | d14 | d21 | d7 | d14 | d21 | d7 | d21 | ||
165 | 106 | + | + | + | + | + | + | + | + |
105 | + | + | + | + | + | + | - | + | |
104 | + | + | + | + | - | + | - | - | |
103 | - | - | - | - | - | - | - | - | |
102 | - | - | - | - | - | - | - | - | |
186 | 106 | + | + | + | + | + | + | + | + |
105 | + | + | + | + | + | + | - | + | |
104 | - | - | + | - | - | - | - | - | |
103 | - | - | - | - | - | - | - | - | |
102 | - | - | - | - | - | - | - | - |
Data are derived from triplicate real-time PCR reactions on cellular DNA (2-LTR CJ, infectious supernatant) or cDNA (FIV gag RNA) on day 7 (d7), day 14 (d14), or day 21 (d21). Infectious supernatant was detected by the presence of FIV DNA in SPF PBMC cultured for 7 days with clarified supernatants.
3. Chromatin Status
We hypothesized that histone proteins physically associated with the FIV proviral promoter in latently-infected CD4+ T-cells would possess epigenetic modifications associated with a condensed chromatin structure [10]. PBMC and CD4+ T-cells were isolated from chronically infected cats as described above, and confirmed to be latently infected by detection of FIV gag DNA in the absence of detectable FIV gag RNA or 2-LTR circle junction DNA via real-time PCR [5]. Chromatin immunoprecipitation (ChIP) was performed on these cells by methods described elsewhere [11], using polyclonal rabbit IgG antibodies against either acetylated histone H3 (H3K9,14ac, Millipore), methylated histone H3 (H3K27me3, Millipore), or RNA polymerase II (Abcam). All antibodies were validated for detection of feline proteins in feline PBMC by Western blot (Figure 2), with polyclonal rabbit IgG (Millipore) used as an isotype control. Following ChIP, DNA was assayed by real-time PCR for the 5’ FIV LTR, with a forward primer in U3/R and reverse primer in the gag leader sequence, and concurrently for the feline housekeeping gene GAPDH. As a comparison to latent infection, cultures of PBMC and enriched CD4+ T-cells from infected cats were activated with mitogens ex vivo [5], confirmed to be transcriptionally active (detectable FIV gag RNA and 2-LTR circle junction DNA), and then examined by ChIP. Positive controls were cultures of PBMC or CD4+ T-cells, obtained from healthy uninfected cats, which were inoculated with FIV in vitro; uninfected cells served as a negative control for the assay.
ChIP analysis showed that the viral promoter in PBMC (Figure 3a) and peripheral CD4+ T-cells from FIV-infected cats (Figure 4a) was not associated with acetylated H3. However, an association with acetylated H3 was readily detected in the ChIP analysis of the viral promoter in cells activated ex vivo with mitogens or infected in vitro (Figure 3b, Figure 4b-c). This relationship remained consistent when immunoprecipitated (IP) DNA from transcriptionally active cells was diluted to a level which enabled normalization of the input FIV promoter DNA from both active and inactive cell types (data not shown). After amplification by real-time PCR, amplicons were electrophoresed on agarose gel to visualize the IP band in active cell types (Figure 3c). This band was purified from the gel, sequenced, and determined to be identical to the consensus sequence of inoculating virus (data not shown). Uninfected cats were negative for FIV LTR sequences in all DNA isolated from ChIP experiments. In CD4+ T-cells, the latent FIV promoter was associated with both methylated H3 (Figure 5a) and RNA polymerase II (Figure 5b); this association was not detected in transcriptionally active cells. These data suggest that the local chromatin environment of the in vivo-derived transcriptionally latent FIV promoter is repressive in nature (histone deacetylation and methylation), which may contribute to the transcriptional inactivity of the viral promoter. Furthermore, as demonstrated in vitro for HIV [12,13], the data indicate that RNA polymerase II remains paused on the FIV LTR.
4. Short Transcripts
To characterize the FIV transcriptional profile during latency, RNA was isolated using TRIzol (Invitrogen) from freshly isolated, latently infected (as defined by lack of viral gag mRNA) CD4+ T-cells and assayed for promoter-proximal short FIV transcripts by real-time PCR. Such short transcripts are consistent with pausing of the RNA polymerase complex [14]. Primer sets for FIV gag capsid, a 66-nucleotide region of R (+1 to +66), a 118-nucleotide region of R-U5 (+1 to +118), and an 87-nucleotide region at the 3’ terminus of the orfA gene were used. Only the short R fragment could be detected in freshly-isolated, latent CD4+ T-cells (Table 2). Copy number was normalized to GAPDH cDNA, and all viral transcripts (gag, R, R-U5, orfA) were detected in cells with active FIV replication. These data suggest that RNA polymerase II paused on the FIV promoter has limited processivity, as observed in PBMC from individuals infected with HIV [15], thereby transcribing a short R segment, but not extending into the viral gag gene (necessary for viral replication). This is particularly intriguing given that FIV is not known to encode a potent transcriptional transactivator (like HIV Tat) [16,17], and may imply that the promoter-associated repressive chromatin structure itself is highly relevant to latency.
Table 2.
Cat Number | Gag Copies | R Copies | R-U5 Copies | OrfA Copies |
---|---|---|---|---|
165 | BLD | 16,000 (±2,000) | BLD | BLD |
184 | BLD | 30,000 (±20,000) | BLD | BLD |
186 | BLD | 3,900 (±900) | BLD | BLD |
187 | BLD | 20,000 (±10,000) | BLD | BLD |
184(A) | 1,600 (±100) | 690,000 (±60,000) | 1,200 (±100) | 3,100 (±300) |
Data are presented as the mean (± standard deviation) of triplicate PCR measurements per 106 copies feline GAPDH cDNA, and are representative of CD4+ T-cell isolation at two different time points (30–34 months post FIV infection) for each cat. Sample labeled 184(A) represents PBMC from cat 184 during a period of viral activation in blood monocytes; BLD indicates values below the limit of detection.
5. Conclusions
In summary, this study demonstrated similarity in T-cell proviral loads and infectious virus between FIV-infected cats and HIV-infected individuals, as well as parallels between the in vivo transcriptional status of each of these viruses in their respective hosts’ CD4+ T-cells. Importantly, we implicated chromatin remodeling in the regulation of the latent FIV promoter in vivo; similarly, in vitro studies support the role of post-translational modifications of histones in the control of HIV-1 transcription [10]. During highly active antiretroviral therapy (HAART), HIV persists in infected individuals as a transcriptionally inactive (latent) integrated provirus [18], and memory CD4+ T-cells are the primary long-lived lentiviral reservoir [19,20,21]. Multiple molecular mechanisms may underlie the establishment and maintenance of latently infected cellular reservoirs [10,22], including epigenetic modification of histone proteins in chromatin [23,24,25]. Accordingly, FIV-infected cats provide an in vivo model of lentiviral latency in its natural host and may help to address questions that are either logistically or ethically not feasible to explore in HIV-infected humans, including the investigation of novel anti-latency therapeutic approaches [26].
Acknowledgements
The authors are grateful for the excellent animal care provided by the staff of the University of California Davis Feline Research Laboratory, for the technical expertise provided by Xinbin Chen and Yingjuan Qian, for statistical assistance by Christopher Barker, and for editing assistance provided by Kirsten Murphy. Funding for this study was provided, in part, by the Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis, and NIH T32 training grants #RR021312 and #5TL1RR024145.
Competing Interests
The authors declare that they have no competing interests.
References
- 1.Kanzaki L.I., Looney D.J. Feline immunodeficiency virus: A concise review. Front. Biosci. 2004;9:370–377. doi: 10.2741/1235. [DOI] [PubMed] [Google Scholar]
- 2.Burkhard M.J., Dean G.A. Transmission and immunopathogenesis of fiv in cats as a model for hiv. Curr. HIV Res. 2003;1:15–29. doi: 10.2174/1570162033352101. [DOI] [PubMed] [Google Scholar]
- 3.Elder J.H., Lin Y.C., Fink E., Grant C.K. Feline immunodeficiency virus (fiv) as a model for study of lentivirus infections: Parallels with hiv. Curr. HIV Res. 2010;8:73–80. doi: 10.2174/157016210790416389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Diehl L.J., Mathiason-Dubard C.K., O’Neil L.L., Obert L.A., Hoover E.A. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J. Virol. 1995;69:6149–6157. doi: 10.1128/jvi.69.10.6149-6157.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Murphy B., Vapniarsky N., Hillman C., Castillo D., McDonnel S., Moore P., Luciw P.A., Sparger E.E. Fiv establishes a latent infection in feline peripheral blood cd4+ t lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology. 2012;9 doi: 10.1186/1742-4690-9-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., et al. Quantification of latent tissue reservoirs and total body viral load in hiv-1 infection. Nature. 1997;387:183–188. doi: 10.1038/387183a0. [DOI] [PubMed] [Google Scholar]
- 7.Josefsson L., King M.S., Makitalo B., Brannstrom J., Shao W., Maldarelli F., Kearney M.F., Hu W.S., Chen J., Gaines H., et al. Majority of cd4+ t cells from peripheral blood of hiv-1-infected individuals contain only one hiv DNA molecule. Proc. Natl. Acad. Sci. USA. 2011;108:11199–11204. doi: 10.1073/pnas.1107729108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Pedersen N.C., Leutenegger C.M., Woo J., Higgins J. Virulence differences between two field isolates of feline immunodeficiency virus (fiv-apetaluma and fiv-cpgammar) in young adult specific pathogen free cats. Vet. Immunol. Immunopathol. 2001;79:53–67. doi: 10.1016/S0165-2427(01)00252-5. [DOI] [PubMed] [Google Scholar]
- 9.Pace M.J., Agosto L., Graf E.H., O’Doherty U. Hiv reservoirs and latency models. Virology. 2011;411:344–354. doi: 10.1016/j.virol.2010.12.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Colin L., van Lint C. Molecular control of hiv-1 postintegration latency: Implications for the development of new therapeutic strategies. Retrovirology. 2009;6 doi: 10.1186/1742-4690-6-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Liu G., Xia T., Chen X. The activation domains, the proline-rich domain, and the c-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/creb-binding protei. J. Biol. Chem. 2003;278:17557–17565. doi: 10.1074/jbc.M210696200. [DOI] [PubMed] [Google Scholar]
- 12.Zhang Z., Klatt A., Gilmour D.S., Henderson A.J. Negative elongation factor nelf represses human immunodeficiency virus transcription by pausing the rna polymerase II complex. J. Biol. Chem. 2007;282:16981–16988. doi: 10.1074/jbc.M610688200. [DOI] [PubMed] [Google Scholar]
- 13.Lenasi T., Contreras X., Peterlin B.M. Transcriptional interference antagonizes proviral gene expression to promote hiv latency. Cell Host Microbe. 2008;4:123–133. doi: 10.1016/j.chom.2008.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Peterlin B.M., Price D.H. Controlling the elongation phase of transcription with p-tefb. Mol. Cell. 2006;23:297–305. doi: 10.1016/j.molcel.2006.06.014. [DOI] [PubMed] [Google Scholar]
- 15.Adams M., Sharmeen L., Kimpton J., Romeo J.M., Garcia J.V., Peterlin B.M., Groudine M., Emerman M. Cellular latency in human immunodeficiency virus-infected individuals with high cd4 levels can be detected by the presence of promoter-proximal transcripts. Proc. Natl. Acad. Sci. USA. 1994;91:3862–3866. doi: 10.1073/pnas.91.9.3862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chatterji U., de Parseval A., Elder J.H. Feline immunodeficiency virus orfa is distinct from other lentivirus transactivators. J. Virol. 2002;76:9624–9634. doi: 10.1128/JVI.76.19.9624-9634.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gemeniano M.C., Sawai E.T., Leutenegger C.M., Sparger E.E. Feline immunodeficiency virus orf-ais required for virus particle formation and virus infectivity. J. Virol. 2003;77:8819–8830. doi: 10.1128/JVI.77.16.8819-8830.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Trono D., Van Lint C., Rouzioux C., Verdin E., Barre-Sinoussi F., Chun T.W., Chomont N. Hiv persistence and the prospect of long-term drug-free remissions for hiv-infected individuals. Science. 2010;329:174–180. doi: 10.1126/science.1191047. [DOI] [PubMed] [Google Scholar]
- 19.Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., Boucher G., Boulassel M.R., Ghattas G., Brenchley J.M., et al. Hiv reservoir size and persistence are driven by t cell survival and homeostatic proliferation. Nat. Med. 2009;15:893–900. doi: 10.1038/nm.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in hiv-1 infection. Annu. Rev. Med. 2002;53:557–593. doi: 10.1146/annurev.med.53.082901.104024. [DOI] [PubMed] [Google Scholar]
- 21.Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible hiv-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 1997;94:13193–13197. doi: 10.1073/pnas.94.24.13193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Margolis D.M. Mechanisms of hiv latency: An emerging picture of complexity. Curr. HIV/AIDS Rep. 2010;7:37–43. doi: 10.1007/s11904-009-0033-9. [DOI] [PubMed] [Google Scholar]
- 23.Imai K., Togami H., Okamoto T. Involvement of histone h3 lysine 9 (h3k9) methyltransferase g9a in the maintenance of hiv-1 latency and its reactivation by bix01294. J. Biol. Chem. 2010;285:16538–16545. doi: 10.1074/jbc.M110.103531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Margolis D.M. Histone deacetylase inhibitors and hiv latency. Curr. Opin. HIV AIDS. 2011;6:25–29. doi: 10.1097/COH.0b013e328341242d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Friedman J., Cho W.K., Chu C.K., Keedy K.S., Archin N.M., Margolis D.M., Karn J. Epigenetic silencing of hiv-1 by the histone h3 lysine 27 methyltransferase enhancer of zeste 2. J. Virol. 2011;85:9078–9089. doi: 10.1128/JVI.00836-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Geeraert L., Kraus G., Pomerantz R.J. Hide-and-seek: The challenge of viral persistence in hiv-1 infection. Annu. Rev. Med. 2008;59:487–501. doi: 10.1146/annurev.med.59.062806.123001. [DOI] [PubMed] [Google Scholar]